Wedbush Adjusts Beam Therapeutics PT to $28 From $65, Maintains Outperform Rating
MT newswire2026/10/27 14:58Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Profit surges 7-fold, revenue breaks 100 trillions for the first time: SK hynix (SKHY.US) responds to AI bubble concerns with record-breaking quarterly report
SK Hynix reported an operating profit of 83.3 trillion won for the third quarter, surpassing expectations, and announced shareholder returns of approximately 100 trillion won within the year.
AstraZeneca (AZN.US) CEO hints at entry into cancer vaccines: years of experience with mRNA technology and more updates expected in the coming months
AstraZeneca is considering developing a cancer vaccine, with the CEO stating that the company has already accumulated experience in mRNA technology. Personalized vaccines have reduced the recurrence rate of melanoma by 42%, but cost and production capacity remain obstacles to broader adoption.
SpaceX (SPCX.US) enters Bank of America's "US 1" preferred stock list as Wall Street renews its confidence in Musk's long-term space vision.
Bank of America Securities released a research report on Tuesday, adding SpaceX to its "US 1" list of preferred investment targets, signaling increased confidence in the outlook for the company led by Elon Musk.
Crypto prices
More
